News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NanoBio Corporation Secures Novel Antigen Source Through National Institutes of Health (NIH) for its Intranasal RSV Vaccine


8/3/2011 9:48:31 AM

ANN ARBOR, Mich.--(BUSINESS WIRE)--NanoBio® Corporation today announced a licensing agreement with the National Institutes of Health (NIH) that represents a significant step forward in developing the first vaccine to protect against respiratory syncytial virus (RSV) infections. The agreement provides NanoBio with rights to a novel RSV antigen, developed by the NIH using proprietary viral-selection and reverse-genetics technology.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES